Study EvAluating Genotypes While Using Lucentis 2

Summary

Study EvAluating Genotypes While Using Lucentis 2 is a clinical trial^[1].

Key Facts

• Study EvAluating Genotypes While Using Lucentis 2 is in the country of United States^[2].
• Study EvAluating Genotypes While Using Lucentis 2's instance of is recorded as clinical trial^[3].
• Study EvAluating Genotypes While Using Lucentis 2's start time is recorded as +2008-05-31T00:00:00Z^[4].
• Study EvAluating Genotypes While Using Lucentis 2's end time is recorded as +2011-12-31T00:00:00Z^[5].
• Study EvAluating Genotypes While Using Lucentis 2's sponsor is recorded as University of California, San Diego^[6].
• Study EvAluating Genotypes While Using Lucentis 2's main subject is recorded as macular degeneration^[7].
• Study EvAluating Genotypes While Using Lucentis 2's number of participants is recorded as {'unit': '1', 'amount': '+66'}^[8].
• Study EvAluating Genotypes While Using Lucentis 2's title is recorded as VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis^[9].
• Study EvAluating Genotypes While Using Lucentis 2's short name is recorded as SEAGUL2^[10].
• Study EvAluating Genotypes While Using Lucentis 2's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+50'}^[11].
• Study EvAluating Genotypes While Using Lucentis 2's ClinicalTrials.gov ID is recorded as NCT01464723^[12].
• Study EvAluating Genotypes While Using Lucentis 2's research intervention is recorded as ranibizumab^[13].
• Study EvAluating Genotypes While Using Lucentis 2's clinical trial phase is recorded as phase IV clinical trial^[14].
• Study EvAluating Genotypes While Using Lucentis 2's research subject recruitment status is recorded as completed^[15].
• Study EvAluating Genotypes While Using Lucentis 2's study type is recorded as interventional study^[16].